Chun Helen M, Osawe Sophia, Adams-Dabban Samuel, Favaloro Jennifer, Iriemenam Nnaemeka C, Dirlikov Emilio, Martin Diana, Milligan Kyle, Abutu Andrew, Okunoye Olumide, Okoli Mary, Akanbi Olusola, Akinmulero Oluwaseun, Okonkwo Rita, Oyedele Oyewole, Greby Stacie, Abimiku Alash'le, Okoye McPaul I J, Shiraishi Ray W
Division of Global HIV & Tuberculosis, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Institute of Human Virology, Abuja, Federal Capital Territory, Nigeria.
Int J Infect Dis. 2025 Feb;151:107309. doi: 10.1016/j.ijid.2024.107309. Epub 2024 Nov 21.
Evidence indicates that people living with HIV (PLHIV) are more impacted by COVID-19. The burden of SARS-CoV-2 infection among PLHIV is unknown in Nigeria.
We conducted repeated cross-sectional SARS-CoV-2 serosurveys in 14 states and the Federal Capital Territory in Nigeria among PLHIV who had an HIV viral load (VL) test during April 2022 to January 2023. Evidence of SARS-CoV-2 immunoglobulin G (IgG) antibodies was assessed using a multiplex bead assay to measure IgG to spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins to identify potential infection and/or vaccination status.
Between April 2022 and January 2023, 47,614 remnant VL samples were included and tested for SARS-CoV-2 antibodies. Seroprevalence of SARS-CoV-2 infection, defined as IgG antibodies to spike and RBD591 [S+] and nucleocapsid [N+], (S+N+), ranged between 21.1% (95% confidence intervals [CI]: 11.4-31.8) in Ekiti State in January 2023 to 71.4% (95% CI 71.9-81.9) in Gombe State in November 2022, with overall steady trends within and between states over time, across age and sex.
High rates of SARS-CoV-2 antibody seroprevalence among PLHIV in Nigeria were observed. This underscores the need to understand the association between HIV and SARS-CoV-2 to inform strategies to reduce the threat posed by COVID-19.
有证据表明，艾滋病病毒感染者（PLHIV）受新冠病毒病（COVID-19）的影响更大。在尼日利亚，艾滋病病毒感染者中感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的负担尚不清楚。
我们在尼日利亚的14个州和联邦首都地区对2022年4月至2023年1月期间进行了艾滋病病毒载量（VL）检测的艾滋病病毒感染者进行了反复的横断面SARS-CoV-2血清学调查。使用多重微珠分析评估SARS-CoV-2免疫球蛋白G（IgG）抗体的证据，以测量针对刺突（S）、受体结合域（RBD）和核衣壳（N）蛋白的IgG，以确定潜在的感染和/或疫苗接种状态。
在2022年4月至2023年1月期间，共纳入47,614份残余VL样本并检测SARS-CoV-2抗体。SARS-CoV-2感染的血清阳性率定义为针对刺突和RBD591 [S+]以及核衣壳 [N+]的IgG抗体，（S+N+），范围从2023年1月埃基蒂州的21.1%（95%置信区间 [CI]：11.4 - 31.8）到2022年11月贡贝州的71.4%（95% CI 71.9 - 81.9），随着时间推移，在各年龄和性别组中，州内和州间总体呈稳定趋势。
在尼日利亚的艾滋病病毒感染者中观察到较高的SARS-CoV-2抗体血清阳性率。这凸显了了解艾滋病病毒与SARS-CoV-2之间关联的必要性，以便为减少COVID-19造成的威胁的策略提供信息。
